<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25223">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02778399</url>
  </required_header>
  <id_info>
    <org_study_id>15-OBE2109-001</org_study_id>
    <nct_id>NCT02778399</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis</brief_title>
  <acronym>EDELWEISS</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Phase 2b Dose-ranging Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Associated Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ObsEva SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ObsEva SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the efficacy and safety of a range of oral
      doses of OBE2109 versus placebo, in reducing endometriosis associated pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective, dose-finding, randomized, parallel group, double-blind,
      placebo-controlled phase 2b study investigating the efficacy and safety of OBE2109 in the
      treatment of 330 women with moderate-to-severe endometriosis associated pain.

      Subject will be randomized to one of 6 treatment groups in a 1:1:1:1:1:1 ratio (1 placebo
      group, 5 dose groups with different dosage/regimen).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endometriosis associated pelvic pain score</measure>
    <time_frame>From baseline to week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endometriosis associated pelvic pain scores</measure>
    <time_frame>From baseline up to week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endometriosis associated pelvic pain scores for days with uterine bleeding</measure>
    <time_frame>From baseline up to week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endometriosis associated pelvic pain scores for days with no uterine bleeding</measure>
    <time_frame>From baseline up to week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspareunia score</measure>
    <time_frame>Up to week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyschezia score</measure>
    <time_frame>Up to week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of analgesics</measure>
    <time_frame>Up to week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endometriosis Health Profile-30 (EHP-30) score</measure>
    <time_frame>Up to week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGIC) score</measure>
    <time_frame>Up to week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient status score</measure>
    <time_frame>Up to week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Biberoglu &amp; Behrman (mB&amp;B) score</measure>
    <time_frame>Up to week 36</time_frame>
    <description>The severity of subject reported pain symptoms of endometriosis and physician findings of endometriosis according to the mB&amp;B scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difficulty in doing daily activities score</measure>
    <time_frame>Up to week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Mineral Density (BMD)</measure>
    <time_frame>From baseline up to week 48</time_frame>
    <description>Change from baseline up to week 48 in BMD assessed by dual-energy X-ray absorptiometry (DXA) scan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endometrial biopsies</measure>
    <time_frame>From baseline up to week 36</time_frame>
    <description>Any pathological changes from baseline in the endometrium assessed by histology from endometrial biopsies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transvaginal ultrasound (TVUS) endometrial thickness</measure>
    <time_frame>From baseline up to week 36</time_frame>
    <description>Any pathological changes from baseline in the endometrium.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to week 48.</time_frame>
    <description>Treatment emergent adverse events frequency and severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical laboratory assessments and vital signs</measure>
    <time_frame>From baseline up to week 36</time_frame>
    <description>Change from baseline in clinical laboratory assessments and vital signs.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>OBE2109 dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>OBE2109 dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>OBE2109 dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>OBE2109 dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>OBE2109 dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo / OBE2109 dose 6</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets for oral administration once daily</description>
    <arm_group_label>Placebo / OBE2109 dose 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OBE2109</intervention_name>
    <description>OBE2109 tablets for oral administration once daily</description>
    <arm_group_label>OBE2109 dose 1</arm_group_label>
    <arm_group_label>OBE2109 dose 2</arm_group_label>
    <arm_group_label>OBE2109 dose 3</arm_group_label>
    <arm_group_label>OBE2109 dose 4</arm_group_label>
    <arm_group_label>OBE2109 dose 5</arm_group_label>
    <arm_group_label>Placebo / OBE2109 dose 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  The subject must have had surgically and - if available - histologically confirmed
             pelvic endometriosis up to 7 years before screening.

          -  The subject has moderate to severe endometriosis-associated pain during the screening
             period.

          -  The subject has regular menstrual cycles.

          -  The subject has a BMI ≥ 18 kg/m2 and ≤ 39 kg/m2 at the screening visit.

        Key Exclusion Criteria:

          -  The subject is pregnant or breast feeding or is planning a pregnancy within the
             duration of the treatment period of the study.

          -  The subject had an interventional surgery for endometriosis performed within a period
             of 60 days before screening.

          -  The subject did not respond to prior treatment with gonadotropin releasing hormone
             (GnRH) agonists or GnRH antagonists for endometriosis.

          -  The subject has a history of, or known osteoporosis or other metabolic bone disease.

          -  The subject has chronic pelvic pain that is not caused by endometriosis and requires
             chronic analgesic / therapy, or that would interfere with the assessment of
             endometriosis related pain.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ObsEva SA</last_name>
    <role>Study Director</role>
    <affiliation>Geneva</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chief Medical Officer</last_name>
  </overall_contact>
  <location>
    <facility>
      <name>Site reference ID 455</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 439</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 405</name>
      <address>
        <city>Chino</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 431</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 440</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 450</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 425</name>
      <address>
        <city>Longmont</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 410</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 457</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 418</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 437</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 458</name>
      <address>
        <city>Jensen Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 420</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 441</name>
      <address>
        <city>miami Springs</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 411</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 424</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 435</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 423</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 426</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 442</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 428</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 459</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 404</name>
      <address>
        <city>Shawnee</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 456</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 454</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 453</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 445</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 430</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 409</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 427</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 421</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 436</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 433</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 443</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 415</name>
      <address>
        <city>Tiffin</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 414</name>
      <address>
        <city>Westerville</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 419</name>
      <address>
        <city>Bryn Mawr</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 449</name>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 408</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 403</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 429</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 452</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 447</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 460</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 413</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 434</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 451</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 402</name>
      <address>
        <city>Schertz</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 432</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 422</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 407</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 412</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 417</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 406</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clninicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 101</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 102</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 104</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 105</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 103</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 201</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 202</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 203</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 204</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 205</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 305</name>
      <address>
        <city>Ivana Frankivsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reefrence ID 303</name>
      <address>
        <city>Kyyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 301</name>
      <address>
        <city>Kyyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site reference ID 302</name>
      <address>
        <city>Kyyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SIte reference ID 304</name>
      <address>
        <city>Kyyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 2, 2017</lastchanged_date>
  <firstreceived_date>May 3, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pelvic Pain</keyword>
  <keyword>Endometriosis</keyword>
  <keyword>Dysmenorrhea</keyword>
  <keyword>Dyspareunia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
